KNSA · Kiniksa Pharmaceuticals Interna
$62.84
+25.03% last session
End-of-day data · updated 2026-07-28
Market cap
$5B
Enterprise value
$4B
Trailing P/E
69.8
Forward P/E
37.3
Dividend yield
—
Beta
0.07
Avg volume
1M
Employees
0K
2D change
—
5D change
0.77%
10D change
-0.65%
30D change
7.32%
60D change
31.32%
MTD change
1.03%
YTD change
54.02%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — KNSA
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-23
Latest call per bank · past 12 months
Goldman Sachs
Buy$75.00
+19.4% vs priceWells Fargo
Overweight$74.00
+17.8% vs priceCitigroup
Buy$60.00
-4.5% vs priceJefferies
Buy$71.00
+13.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-23 | Goldman Sachs | Maintains | Buy | $60.00 → $75.00 |
| 2026-07-13 | Wells Fargo | Maintains | Overweight | $57.00 → $74.00 |
| 2026-06-29 | Wedbush | Maintains | Outperform | $59.00 → $72.00 |
| 2026-04-29 | Canaccord Genuity | Maintains | Buy | $62.00 → $64.00 |
| 2026-04-29 | Citigroup | Maintains | Buy | $50.00 → $60.00 |
| 2026-04-29 | Wedbush | Maintains | Outperform | $58.00 → $59.00 |
| 2026-04-29 | Wells Fargo | Maintains | Overweight | $53.00 → $57.00 |
| 2026-04-28 | Jefferies | Maintains | Buy | $58.00 → $71.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 78 — overbought territory; the recent run-up may be due for a pause.
- Price vs 50-day MA: Trading 38.6% above the 50-day MA ($57.32).
- Price vs 200-day MA: Trading 68.1% above the 200-day MA ($47.25).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is positive (+0.65) — short-term momentum is improving.
- 52-week range: Price is within 5% of the 52-week high ($79.44).
KNSA Price Chart
Loading chart for KNSA…
Fundamentals
About Kiniksa Pharmaceuticals Interna
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
More in Drug Manufacturers - Specialty & Generic
TAK
Takeda Pharmaceutical Company L
$56B 11.9% YTD
HLN
Haleon plc
$44B -0.4% YTD
TEVA
Teva Pharmaceutical Industries
$36B -0.4% YTD
ZTS
Zoetis Inc.
$32B -37.9% YTD
UTHR
United Therapeutics Corporation
$26B 8.3% YTD
VTRS
Viatris Inc.
$21B 43.9% YTD
NBIX
Neurocrine Biosciences, Inc.
$18B 24.4% YTD
ELAN
Elanco Animal Health Incorporat
$13B 12.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.